Literature DB >> 9746448

Panic attacks with psychotic features.

I Galynker1, C Ieronimo, A Perez-Acquino, Y Lee, A Winston.   

Abstract

BACKGROUND: Anxiety disorders are among the most frequently diagnosed group of psychiatric disorders in the general population. Although anxiety disorders are often comorbid with depression and personality disorders, they rarely culminate in psychosis.
METHOD: Having observed psychosis in the course of a severe panic attack, the authors prospectively identified four patients who experienced panic attacks with co-occurring psychosis. All met the DSM-IV criteria for panic disorder. Distinctive features of their clinical presentation, pharmacotherapy, and follow-up were recorded.
RESULTS: Three patients had a history of panic disorder, and one had a history of generalized anxiety disorder. In all cases, psychosis (auditory hallucinations or delusions) originated in the course of a severe panic attack. Psychotic symptoms occurred only during panic attacks; however, these could occur up to 10 to 15 times a day. In all four patients, psychotic symptoms resolved after a brief time either spontaneously or with benzodiazepine/SSRI treatment. None of the patients required neuroleptic treatment.
CONCLUSION: The cases suggest that psychosis may develop in the course of a severe panic attack in patients with panic disorder, as was reported previously for patients with obsessive-compulsive disorder and posttraumatic stress disorder. Distinguishing panic attacks with psychotic features from other psychotic disorders is clinically important since antipsychotic medication treatment for these psychotic symptoms is not indicated. Further research on the prevalence of psychotic symptoms in the anxiety disorders and the pathophysiology of this phenomenon is required to clarify the relationship between the anxiety disorders and psychosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9746448

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

1.  Prevalence and correlates of psychotic symptoms among Asian males.

Authors:  Mythily Subramaniam; Swapna Verma; Christopher Cheok; I-Min Lee; John Wong; Siow Ann Chong
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-11-03       Impact factor: 4.328

2.  Anxiety Disorders and Perceptual Disturbances in Adolescents with 22q11.2 Deletion Syndrome Treated with SSRI: A Case Series.

Authors:  Andrea C Stachon; Claire De Souza
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2011-11

3.  Emergency room validation of the revised Suicide Trigger Scale (STS-3): a measure of a hypothesized suicide trigger state.

Authors:  Zimri S Yaseen; Evan Gilmer; Janki Modi; Lisa J Cohen; Igor I Galynker
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

4.  Construct development: The Suicide Trigger Scale (STS-2), a measure of a hypothesized suicide trigger state.

Authors:  Zimri Yaseen; Curren Katz; Matthew S Johnson; Daniel Eisenberg; Lisa J Cohen; Igor I Galynker
Journal:  BMC Psychiatry       Date:  2010-12-14       Impact factor: 3.630

5.  Case report of visual hallucinations in anxiety.

Authors:  Sachdeva Ankur; Saxena Ankit; Kandpal Manish
Journal:  Shanghai Arch Psychiatry       Date:  2015-04-25

Review 6.  Anxiety disorders and schizophrenia.

Authors:  Jacqueline E Muller; Liezl Koen; Seedat Soraya; Robin A Emsley; Daniel J Stein
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 8.081

7.  COVID-19-associated brief psychotic disorder.

Authors:  Colin M Smith; Jonathan R Komisar; Ahmad Mourad; Brian R Kincaid
Journal:  BMJ Case Rep       Date:  2020-08-11

Review 8.  Candidate Biomarkers of Suicide Crisis Syndrome: What to Test Next? A Concept Paper.

Authors:  Raffaella Calati; Charles B Nemeroff; Jorge Lopez-Castroman; Lisa J Cohen; Igor Galynker
Journal:  Int J Neuropsychopharmacol       Date:  2020-04-21       Impact factor: 5.176

Review 9.  Pivotal mental states.

Authors:  Ari Brouwer; Robin Lester Carhart-Harris
Journal:  J Psychopharmacol       Date:  2020-11-11       Impact factor: 4.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.